Bioretec Ltd reports improved H1 2026 results
Bioretec Ltd released its first half-year report for 2026, showing significant net sales growth compared to the previous year. The company also reported an improved adjusted sales margin.
Helsinki – Bioretec Ltd announced on August 13, 2026, its financial results for the first half of 2026. The company reported net sales of EUR 1,100 thousand for the period of January–June 2026, a substantial increase from EUR 678 thousand in the same period last year.
The adjusted sales margin rose to 68.0% of net sales, up from 57.1% in the first half of 2025. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at EUR -2,251 thousand, an improvement from EUR -3,321 thousand in the prior year's comparable period.
Bioretec focuses on the development and manufacturing of bioresorbable bone surgical implants, primarily used in orthopedic and trauma surgery.
The half-year report is unaudited. The company did not provide specific details for the second quarter's performance in this release but anticipates further results improvement moving forward.